With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.
PEP trades against a final fair-value range of $142.66-$206.45, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
A sustained macroeconomic downturn coupled with accelerated adoption of GLP-1 weight-loss drugs leads to structural volume declines and an inability to offset cost inflation through pricing, heavily compressing operating margins and driving free cash flowFree cash flowOperating cash flow minus capital expenditures. The cash a business generates after maintaining and growing its asset base — the closest accounting proxy for owner-economics. below historical norms.
Mass adoption of appetite-suppressing GLP-1 drugs permanently reduces per-capita consumption of high-calorie snacks and sugary beverages, breaking historical volume baselines.
Consumer fatigue over successive price hikes forces aggressive discounting and promotional activity to defend market share against private label brands, destroying gross margins.
Extreme agricultural commodity inflation and localized supply chain disruptions structurally elevate the cost base beyond what can be passed to consumers, permanently compressing operating margins.
| Line item | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
|---|---|---|---|---|---|
| Revenue | $86.39B | $91.47B+5.9% | $91.85B+0.4% | $93.93B+2.3% | +2.8% |
| Gross profit | $45.82B | $49.59B | $50.11B | $50.86B | +3.5% |
| Operating income | $11.36B | $12.91B | $12.92B | $13.49B | +5.9% |
| Net income | $8.91B | $9.07B+1.8% | $9.58B+5.6% | $8.24B-14.0% | -2.6% |
| EPS (diluted) | $6.42 | $6.56 | $6.95 | $6.00 | -2.2% |
| EBITDA | $14.92B | $15.75B | $16.68B | $15.54B | +1.4% |
| R&D | — | — | — | — | — |
| SG&A | $34.46B | $36.68B | $37.19B | $37.37B | +2.7% |
Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Deterioration versus the report thesis |
| Significant downward revisions in forward internal valuation cross-checks earnings. | Monitor | Deterioration versus the report thesis |
| Unplanned increases in promotional spend to clear inventory. | Monitor | Deterioration versus the report thesis |
